NCT06711432 Different Intraoperative Blood Pressure Management on Postoperative Cognitive Function in Tumor Patients（PRECISION）
| NCT ID | NCT06711432 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Zhejiang Cancer Hospital |
| Condition | Tumor |
| Study Type | INTERVENTIONAL |
| Enrollment | 214 participants |
| Start Date | 2024-09-18 |
| Primary Completion | 2026-05-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 214 participants in total. It began in 2024-09-18 with a primary completion date of 2026-05-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a randomized controlled study to explore whether perioperative blood pressure management with different strategies can reduce the incidence of delirium and postoperative cognitive impairment and serious perfusion related complications (persistent hypotension, new heart arrhythmia, cardiac insufficiency, new stroke, sudden death, etc.) within 30 days after stroke in cancer patients at high risk for stroke. Patients were randomly divided into: 1) strict blood pressure management group: norepinephrine or phenylephrine maintenance intraoperative MAP≥85 mmHg, and 2) conventional blood pressure management group: intraoperative routine blood pressure management (MAP≥65mmHg). The study included 424 subjects and was randomized to provide 90% efficacy. Secondary markers were unscrupulous cerebrovascular events (persistent hypotension, arrhythmia, cardiac insufficiency, new stroke, sudden death) within 30 days after surgery.
Eligibility Criteria
Inclusion Criteria: 1. Patients with high-risk stroke (combined with 3 risk factors or more according to the stroke risk screening table) 2. Patients who plan to undergo surgery for abdominal tumors (gynecological, urinary, hepatobiliary, and gastrointestinal tumors) under general anesthesia are expected to have surgery duration \>2 hours 3. The ASA is rated as Class II or III 4. Patients who underwent invasive arterial blood pressure monitoring before surgery signed informed consent Exclusion Criteria: 1. Patients do not want to participate in the study 2. Patients with severe heart disease (severe valvular disease, sick sinus syndrome, high atrioventricular block without pacemaker implantation), grade III or above Liver function impairment (Child-Pugh class C) 3. Need kidney replacement therapy; New stroke \<3 months 4. Emergency surgery 5. Preoperative history of mental illness, epilepsy, Parkinson's disease, or myasthenia gravis 6. Speech, vision, or hearing impairment that prevents completion of a cognitive function assessment 7. Situations where strict blood pressure management is not appropriate, such as controlled hypotension during surgery.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06711432 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 85 Years, studying Tumor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06711432 currently recruiting?
Yes, NCT06711432 is actively recruiting participants. Contact the research team at zhuyejing1983@126.com for enrollment information.
Where is the NCT06711432 trial being conducted?
This trial is being conducted at Hangzhou, China.
Who is sponsoring the NCT06711432 clinical trial?
NCT06711432 is sponsored by Zhejiang Cancer Hospital. The trial plans to enroll 214 participants.